Application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone
The invention relates to an application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone in preparation of a medicine for treating peripheral T cell lymphoma (PTCL). The PTCL is preferably selected from PTCL subjected to primary treatment. On the basis, other firs...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | LI TONG JIA RUNLU LI YANHUI DU YANLING AN NA LI CHUNLEI WANG SHIXIA XIA XUEFANG |
| description | The invention relates to an application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone in preparation of a medicine for treating peripheral T cell lymphoma (PTCL). The PTCL is preferably selected from PTCL subjected to primary treatment. On the basis, other first-line and second-line medicines for treating PTCL can be further used. A method of treating PTCL by administering to a patient a therapeutically effective amount of a liposome of mitoxantrone hydrochloride and cyclophosphamide, vincristine, and prednisone. The combined application of the medicine is safe and tolerant, has small toxic and side effects, and can obtain a higher total objective remission rate (ORR) in the primary treatment of PTCL patients.
盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松在制备用于治疗外周T细胞淋巴瘤(PTCL)的药物中的用途。所述PTCL优选初治的PTCL。还可在上述基础上进一步使用其他治疗PTCL的一线、二线药物。一种治疗PTCL的方法，所述方法为给予患者治疗有效量的盐酸米托蒽醌脂质体和环磷酰胺、长春新碱及强的松。该药物的联合施用安全耐受，毒副作用小，并且能够在初治PTCL患者中获得较高的总客观缓解率(ORR)。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN115955971A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN115955971A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN115955971A3</originalsourceid><addsrcrecordid>eNqNjLEKwjAQhrs4iPoO516HIEU6lqI4ObnXkFzJQXJ3JEHs29vBB3D6h-_7_m3zGlQjOVtJGGSGRFU-lmsWRgiLz-JClEweIZJKkYQtuMVF0SBFg00rauFN7DKVSmtl2YNm9ExlPdk3m9nGgoff7prj7foc7ydUmbCodchYp_FhTNd3XX8xw_kf5wuFVD7C</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone</title><source>esp@cenet</source><creator>LI TONG ; JIA RUNLU ; LI YANHUI ; DU YANLING ; AN NA ; LI CHUNLEI ; WANG SHIXIA ; XIA XUEFANG</creator><creatorcontrib>LI TONG ; JIA RUNLU ; LI YANHUI ; DU YANLING ; AN NA ; LI CHUNLEI ; WANG SHIXIA ; XIA XUEFANG</creatorcontrib><description>The invention relates to an application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone in preparation of a medicine for treating peripheral T cell lymphoma (PTCL). The PTCL is preferably selected from PTCL subjected to primary treatment. On the basis, other first-line and second-line medicines for treating PTCL can be further used. A method of treating PTCL by administering to a patient a therapeutically effective amount of a liposome of mitoxantrone hydrochloride and cyclophosphamide, vincristine, and prednisone. The combined application of the medicine is safe and tolerant, has small toxic and side effects, and can obtain a higher total objective remission rate (ORR) in the primary treatment of PTCL patients.
盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松在制备用于治疗外周T细胞淋巴瘤(PTCL)的药物中的用途。所述PTCL优选初治的PTCL。还可在上述基础上进一步使用其他治疗PTCL的一线、二线药物。一种治疗PTCL的方法，所述方法为给予患者治疗有效量的盐酸米托蒽醌脂质体和环磷酰胺、长春新碱及强的松。该药物的联合施用安全耐受，毒副作用小，并且能够在初治PTCL患者中获得较高的总客观缓解率(ORR)。</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230411&DB=EPODOC&CC=CN&NR=115955971A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230411&DB=EPODOC&CC=CN&NR=115955971A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LI TONG</creatorcontrib><creatorcontrib>JIA RUNLU</creatorcontrib><creatorcontrib>LI YANHUI</creatorcontrib><creatorcontrib>DU YANLING</creatorcontrib><creatorcontrib>AN NA</creatorcontrib><creatorcontrib>LI CHUNLEI</creatorcontrib><creatorcontrib>WANG SHIXIA</creatorcontrib><creatorcontrib>XIA XUEFANG</creatorcontrib><title>Application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone</title><description>The invention relates to an application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone in preparation of a medicine for treating peripheral T cell lymphoma (PTCL). The PTCL is preferably selected from PTCL subjected to primary treatment. On the basis, other first-line and second-line medicines for treating PTCL can be further used. A method of treating PTCL by administering to a patient a therapeutically effective amount of a liposome of mitoxantrone hydrochloride and cyclophosphamide, vincristine, and prednisone. The combined application of the medicine is safe and tolerant, has small toxic and side effects, and can obtain a higher total objective remission rate (ORR) in the primary treatment of PTCL patients.
盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松在制备用于治疗外周T细胞淋巴瘤(PTCL)的药物中的用途。所述PTCL优选初治的PTCL。还可在上述基础上进一步使用其他治疗PTCL的一线、二线药物。一种治疗PTCL的方法，所述方法为给予患者治疗有效量的盐酸米托蒽醌脂质体和环磷酰胺、长春新碱及强的松。该药物的联合施用安全耐受，毒副作用小，并且能够在初治PTCL患者中获得较高的总客观缓解率(ORR)。</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLEKwjAQhrs4iPoO516HIEU6lqI4ObnXkFzJQXJ3JEHs29vBB3D6h-_7_m3zGlQjOVtJGGSGRFU-lmsWRgiLz-JClEweIZJKkYQtuMVF0SBFg00rauFN7DKVSmtl2YNm9ExlPdk3m9nGgoff7prj7foc7ydUmbCodchYp_FhTNd3XX8xw_kf5wuFVD7C</recordid><startdate>20230411</startdate><enddate>20230411</enddate><creator>LI TONG</creator><creator>JIA RUNLU</creator><creator>LI YANHUI</creator><creator>DU YANLING</creator><creator>AN NA</creator><creator>LI CHUNLEI</creator><creator>WANG SHIXIA</creator><creator>XIA XUEFANG</creator><scope>EVB</scope></search><sort><creationdate>20230411</creationdate><title>Application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone</title><author>LI TONG ; JIA RUNLU ; LI YANHUI ; DU YANLING ; AN NA ; LI CHUNLEI ; WANG SHIXIA ; XIA XUEFANG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN115955971A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>LI TONG</creatorcontrib><creatorcontrib>JIA RUNLU</creatorcontrib><creatorcontrib>LI YANHUI</creatorcontrib><creatorcontrib>DU YANLING</creatorcontrib><creatorcontrib>AN NA</creatorcontrib><creatorcontrib>LI CHUNLEI</creatorcontrib><creatorcontrib>WANG SHIXIA</creatorcontrib><creatorcontrib>XIA XUEFANG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LI TONG</au><au>JIA RUNLU</au><au>LI YANHUI</au><au>DU YANLING</au><au>AN NA</au><au>LI CHUNLEI</au><au>WANG SHIXIA</au><au>XIA XUEFANG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone</title><date>2023-04-11</date><risdate>2023</risdate><abstract>The invention relates to an application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone in preparation of a medicine for treating peripheral T cell lymphoma (PTCL). The PTCL is preferably selected from PTCL subjected to primary treatment. On the basis, other first-line and second-line medicines for treating PTCL can be further used. A method of treating PTCL by administering to a patient a therapeutically effective amount of a liposome of mitoxantrone hydrochloride and cyclophosphamide, vincristine, and prednisone. The combined application of the medicine is safe and tolerant, has small toxic and side effects, and can obtain a higher total objective remission rate (ORR) in the primary treatment of PTCL patients.
盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松在制备用于治疗外周T细胞淋巴瘤(PTCL)的药物中的用途。所述PTCL优选初治的PTCL。还可在上述基础上进一步使用其他治疗PTCL的一线、二线药物。一种治疗PTCL的方法，所述方法为给予患者治疗有效量的盐酸米托蒽醌脂质体和环磷酰胺、长春新碱及强的松。该药物的联合施用安全耐受，毒副作用小，并且能够在初治PTCL患者中获得较高的总客观缓解率(ORR)。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN115955971A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | Application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A07%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LI%20TONG&rft.date=2023-04-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN115955971A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |